Brenipatide as a Promising Treatment for Alcohol Use Disorder
In this seriesClinical Pearl5
Why Was This Research Needed?
How effective is once-monthly brenipatide in reducing relapse rates in patients with alcohol use disorder?
Bottom Line
Brenipatide significantly improves abstinence rates and reduces alcohol cravings in patients with alcohol use disorder compared to placebo. It presents a promising new approach for managing this condition.
Study at a Glance
- Study Design
- Phase 2/3 randomized controlled trial
- Population
- 452 adults with moderate to severe alcohol use disorder
- Intervention
- 300 mg once-monthly brenipatide
- Comparator
- Placebo
- Primary Outcome
- Proportion of participants maintaining abstinence over six months
Key Findings
- 68.1% of patients in the brenipatide group remained abstinent compared to 39.8% in the placebo group (OR 3.12; p<0.001).
- Significant reduction in alcohol cravings was observed in the brenipatide group, with a mean difference of -4.3 (p<0.001).
- Quality of life improved significantly among those receiving brenipatide (p=0.003).
- Brenipatide was well-tolerated, with no serious adverse events reported.
Implications for Practice
Clinicians should consider brenipatide as a viable option for patients with alcohol use disorder, particularly in those who have had difficulty achieving abstinence with traditional therapies. Continuous monitoring for efficacy and tolerability is advised.
Caveats & Limitations
Longer-term data on efficacy and safety are needed, and the generalizability of results outside this specific population and setting remains to be evaluated.
This summary was AI-assisted and reviewed by an editor. It does not constitute medical advice. Always consult the original publication and your clinical judgment.